Results from the Atrial fibrillation progression trial (ATTEST) were presented on 31 August at the European Society of Cardiology (ESC) Congress 2019 in Paris, France. ATTEST is the first randomised controlled trial to directly compare the effectiveness of ablation using radiofrequency (RF) catheters versus standard antiarrhythmic drugs (AAD) in delaying atrial fibrillation (AF) progression. The results show that patients treated with catheter ablation (aged 67.8±4.8 years) were almost 10 times less likely to develop persistent AF than patients on AAD at three years after study initiation.
ATTEST was sponsored by Biosense Webster, a global leader in the science of diagnosing and treating heart rhythm disorders and part of Johnson & Johnson Medical Devices Companies. In the study, patients with intermittent AF were treated, according to current guidelines, with either AAD or underwent catheter ablation, an interventional procedure that creates small scars on targeted heart tissue to block abnormal electrical signals that cause arrhythmia. At the end of the study, 17.5% of patients from the AAD group developed persistent AF, while only 2.4% of patients from the catheter ablation group experienced disease progression.
“Progression from intermittent AF to a persistent form of the condition is very common, and with that progression we see an increased risk of stroke and death”, said Karl-Heinz Kuck, lead author for ATTEST. “These results are welcome as they suggest that early use of catheter ablation can significantly delay or prevent the progression of AF more effectively than drug therapy”.
Outcomes from ATTEST were similar to other key recent trials which demonstrated that up to 94% of patients with AF treated with catheter ablation are free from arrhythmia recurrence at one year, with nearly half the chance of death, stroke, cardiac arrest and cardiovascular hospitalisation over seven years, compared to AAD. These studies have also shown that catheter ablation could significantly improve patient quality of life over drug therapy, as well as being a more cost effective option over the long term.
AF is a serious and debilitating condition characterised by an irregular and often fast heart rhythm that results in uncoordinated contraction of the top two chambers of the heart. The irregular heart rhythm may cause blood clots that could lead to a particularly devastating form of stroke. AF is typically a progressive disease, with one in five patients progressing from paroxysmal (intermittent) AF to persistent (constant) AF in one year.16-18
According to a report published by Biosense Webster in 2018, which highlighted the impact and burden of AF, the condition is fast becoming the ‘new millennium epidemic’ and one of the world’s most significant health issues. AF is responsible for disrupting the quality of life of 33 million people worldwide and rising by almost 70% by 2030. It also costs healthcare systems up to €3.286 billion annually in European countries alone. A follow-up report focusing on the treatment of AF will be published in late 2019.
“We are dedicated to advancing the care of—and ultimately curing—AF through focusing on three main areas: innovating new technology solutions, investing in research and publications to advance clinical understanding—as demonstrated by ATTEST—and improving education and awareness of AF among clinicians and the general public,” said Uri Yaron, worldwide president, Biosense Webster. “With approximately 150 electrophysiology (EP) centres involved in research with us globally and a heritage spanning 20 years of pioneering treatment in the field of EP, we are committed to driving progress and healing more hearts. We welcome the findings presented at this morning’s late breaking session, which reinforce the significant benefits of RF catheter ablation in the treatment of AF and should support clinicians in recommending its early use as the gold-standard in AF patient care”.